Why Novo Nordisk Stock Hit a Multi-Year Low

• Novo Nordisk (NVO) fell to a 5-year low of about $43 in September 2026, down roughly 35% over the prior year, after a run of clinical and guidance setbacks.
• The December 2024 CagriSema phase 3 readout showed 22.7% weight loss after 68 weeks, below the company’s projected 25%, wiping as much as $90 billion in market value.
• A July 2025 guidance cut and CEO change erased over $60 billion in market cap in one session.
• Novo guides adjusted sales and operating profit to fall as much as 6% in 2026, while its capital markets day targets failed to reassure investors.
• The recovery case rests on amycretin/zenagamtide, new semaglutide indications, and valuation near 10x earnings, but the US semaglutide patent expires in 2031.

The CagriSema Trial Disappointment

On December 20, 2024, Novo Nordisk (NVO) reported that its experimental obesity drug CagriSema produced 22.7% mean weight loss after 68 weeks in a late-stage trial. That was below the 25% target the company had led investors to expect, Reuters reported. The miss wiped as much as $90 billion off Novo’s market value in a single session.

The market reaction was severe and immediate. US-listed shares fell more than 19%, and CNBC reported the stock plunged roughly 20%. CagriSema was the asset Novo had positioned as its answer to Eli Lilly’s tirzepatide, marketed as Zepbound for obesity and Mounjaro for diabetes. The combination pairs the amylin analogue cagrilintide with semaglutide, the active ingredient in Wegovy and Ozempic.

The disappointment compounded in a second trial. In March 2025, Novo reported that CagriSema delivered 15.7% weight loss at 68 weeks in people with type 2 diabetes, sending the stock lower, Fierce Biotech reported. In two head-to-head trials against Eli Lilly’s tirzepatide, CagriSema fell short. In the REDEFINE 4 obesity study, CagriSema produced 23.0% weight loss versus tirzepatide’s 25.5% and missed non-inferiority on weight. In the REIMAGINE 4 trial in people with type 2 diabetes, CagriSema met non-inferiority on weight loss (about 15.2%) but missed it on blood-sugar (HbA1c) control.

Why the Trial Failed to Meet Expectations

CagriSema’s efficacy was real. A 22.7% mean weight reduction is a substantial clinical result, and it beat placebo by a wide margin. The problem was the gap between that result and what Novo had told investors to expect. Executives had primed the market for at least 25% weight loss, a threshold that would have leapfrogged Lilly’s tirzepatide and reasserted Novo’s leadership in the obesity market.

That framing turned a good result into a failed benchmark. When a company sets an explicit efficacy target and misses it, the market re-prices the entire pipeline on the assumption that management’s forecasts are optimistic. Novo’s second CagriSema trial made this worse by omitting the headline statistic investors wanted: the share of patients who lost at least 25% of body weight.

The competitive context sharpened the reaction. Lilly’s tirzepatide had already shown greater weight loss than Wegovy in head-to-head testing, and Lilly was ahead in developing an oral obesity pill. CagriSema was Novo’s mechanism to close that gap. Missing the target left Novo without a clear near-term answer in a segment where it had once been the undisputed leader.

Market Reaction and Investor Confidence

The CagriSema miss was the first step in a multi-year erosion of investor confidence, not a one-day event. Novo’s all-time high closing price was $135.66 on June 25, 2024, according to Macrotrends. By late August 2026, the stock had dropped about 70% from that peak, MarketWatch reported alongside a Deutsche Bank downgrade to sell.

The next shock came in July 2025. Novo cut its 2025 sales growth forecast to 8% to 14% from a prior 13% to 21% and named Maziar Mike Doustdar, its international operations head, as new CEO. US-listed shares fell more than 20% and erased over $60 billion in market capitalization, BioPharma Dive reported. The company cited cheaper compounded copies of semaglutide, a failed telehealth partnership with Hims & Hers, and a direct-to-consumer program that underdelivered on prescriptions.

Investor confidence took a further hit in July 2026 when Novo’s ziltivekimab missed its primary endpoint in a late-stage heart-disease trial, wiping about $30 billion in market value, Forbes reported. Novo also faces a shareholder lawsuit alleging it misled investors about the CagriSema trial; a US judge allowed parts of the case to proceed in July 2026.

Long-term Outlook and Company Guidance

Novo’s guidance has been unusually volatile. The company guided adjusted sales and operating profit to fall as much as 6% at constant exchange rates for 2026, then raised that outlook after a stronger second quarter, only to see the stock fall 5% because the quality of the beat and Wegovy pill pricing disappointed investors. In its Q2 2026 disclosure, adjusted net sales reached DKK 78.5 billion (about $11.4 billion), up 7% at constant exchange rates, with adjusted operating profit of DKK 33.4 billion, up 11%. The company also recorded DKK 6.3 billion in non-cash impairments, including a DKK 4.0 billion write-off after terminating the oral CB1 drug monlunabant over neuropsychiatric side effects.

By September 2026, Novo’s US-listed ADR had fallen to a 5-year low of about $43, down roughly 35% over the prior year, per Macrotrends data. The stock closed at DKK 260 on Nasdaq Copenhagen on September 21, 2026, down 7.65% after the company’s capital markets day, according to ad-hoc-news.

At that capital markets day in London, Novo promised more than five “multi-blockbusters” by 2030 and over DKK 150 billion (about $23 billion) in risk-adjusted annual pipeline sales by 2035, BioPharma Dive reported. Shares fell as much as 8% in response. Novo currently books roughly $330 billion in annual revenue, so $23 billion of pipeline sales over a decade implies only modest growth, and management framed 2026-to-2030 growth only as “in line” with peers.

The Broader Context of Obesity Drug Trials

Novo’s setbacks stand out because the obesity market itself has not cooled. Patient demand for GLP-1 therapies continues to expand, and Novo says its products reach more than 46 million patients globally. The disconnect is that volume growth no longer translates into the pricing power it once did. Semaglutide was selected for Medicare drug-price negotiation, with a negotiated price of $274 per 30-day supply effective January 2027, roughly 71% below the 2024 list price.

Competition has intensified on every front. Lilly has taken the leading share of the US GLP-1 market, and analysts put Lilly’s US GLP-1 share near 60.9%, with Novo trading at a P/E near 11 versus Lilly’s mid-30s. Novo’s Wegovy pill missed Wall Street expectations in the April-to-June 2026 quarter, and only one Novo drug beyond CagriSema is under FDA review, a hemophilia treatment.

The trial results also land against a shifting patent timeline. Semaglutide’s core US composition-of-matter patent expires in December 2031, and Novo faces loss of protection in Canada and Brazil in late 2026. That window shapes how quickly the company must migrate patients onto successor molecules.

The Role of Pipeline and Growth Strategy

The recovery case runs through the pipeline, and it is specific rather than vague. Amycretin, now assigned the INN zenagamtide, is a single peptide that activates both GLP-1 and amylin receptors. In a phase 2 study in people with type 2 diabetes, once-weekly zenagamtide produced up to 14.6% body weight loss at 36 weeks with no clear plateau at the highest dose. Novo is advancing it in both injectable and oral forms, with phase 3 development in obesity and diabetes set to begin in the second half of 2026.

CagriSema itself remains on track for US chronic weight management filing, and its REDEFINE 3 cardiovascular outcomes trial in about 7,000 patients could replicate the MACE reduction Wegovy showed in the SELECT trial. High-dose oral semaglutide 50 mg showed 15.1% weight loss in the OASIS 1 trial, and Novo has run phase 3 work in MASH and cardiovascular disease. In September 2026, the company reported that semaglutide cut obesity rates in a trial of children aged 6 to under 12, an indication no competitor has secured.

Management has moved aggressively on cost and structure. Under CEO Mike Doustdar, Novo has carried out roughly 9,000 layoffs, reshaped its board, rebranded, partnered with Anthropic on AI drug discovery, and struck pipeline deals including a partnership with Orbis Medicines. Novo committed roughly DKK 55 billion (about $8 billion) in 2026 capital expenditure across manufacturing sites in Clayton, North Carolina; Chartres, France; and Kalundborg, Denmark. Doustdar has said the company can broaden its ambitions again and is weighing M&A beyond obesity.

Surprising Findings

Two data points stand out. First, Novo’s stock had already fallen 35% over the prior year before the September 2026 low, meaning the drawdown was a sustained repricing rather than a single shock. Second, valuation looks cheap by conventional measures. The stock trades near 10.7 times trailing earnings with a dividend yield above 4%, The Motley Fool noted, and analysts expect only about 2% annual growth.

That combination is the crux of the debate. To be fairly valued, Novo would only need to grow earnings about 6% annually over five years, which management seems to be promising less than. A low multiple can attract value buyers, but a cheap multiple cannot fix poor growth, and the 2031 patent cliff arrives before most of the pipeline matures.

Lessons for Investors and Industry

The Novo Nordisk case shows that clinical trial results remain the single most powerful determinant of biotech valuation. A company can lead its market, hold a deep pipeline, and still lose two-thirds of its value when an efficacy benchmark is missed. Novo set an explicit 25% target, missed it, and the market never fully regained confidence in management’s forecasts.

The second lesson is about sequencing. Novo’s pipeline is real, but most of it sits in phase 2 or earlier, while the semaglutide patent clock is already running. A long-term growth story only works if near-term assets deliver. Novo’s guidance cut, its capital markets day disappointment, and its 5-year low all trace back to that timing mismatch.

What to watch next: CagriSema’s FDA filing and approval timing, zenagamtide phase 3 initiation and early readouts, Wegovy pill net pricing, loss of exclusivity in Canada and Brazil in late 2026, and the outcome of shareholder litigation tied to CagriSema disclosures. This is analysis of public disclosures, not investment advice; investors should weigh the patent timeline, competitive dynamics, and pipeline risk against their own time horizons.

Novo Nordisk by the Numbers

Sources and References

Sources cited while researching and writing this article:

• Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps
• Novo cuts guidance, names new CEO as obesity drug challenges mount …
• Novo Nordisk stock falls after cautious growth targets
• Novo talks up drug launches in effort to win back investors | BioPharma Dive
• Why Novo Nordisk Stock Just Crashed | The Motley Fool